PL373432A1 - Sposób leczenia ciężkiej niewydolności serca i lek przeznaczony do leczenia tym sposobem - Google Patents

Sposób leczenia ciężkiej niewydolności serca i lek przeznaczony do leczenia tym sposobem

Info

Publication number
PL373432A1
PL373432A1 PL04373432A PL37343204A PL373432A1 PL 373432 A1 PL373432 A1 PL 373432A1 PL 04373432 A PL04373432 A PL 04373432A PL 37343204 A PL37343204 A PL 37343204A PL 373432 A1 PL373432 A1 PL 373432A1
Authority
PL
Poland
Prior art keywords
heart failure
severe heart
treating severe
medicament therefor
medicament
Prior art date
Application number
PL04373432A
Other languages
English (en)
Other versions
PL218069B1 (pl
Inventor
Atsushi Ozaki
Yosuke Maki
Osamu Sato
Yoshitaka Yamamura
Original Assignee
Otsuka Pharmaceutical Co, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32908667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL373432(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co, Ltd. filed Critical Otsuka Pharmaceutical Co, Ltd.
Publication of PL373432A1 publication Critical patent/PL373432A1/pl
Publication of PL218069B1 publication Critical patent/PL218069B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL373432A 2003-02-24 2004-02-23 Lek i kompozycja farmaceutyczna do zastosowania w leczeniu ciężkiej niewydolności serca oraz zastosowanie 5-hydroksy-7-chloro-1-[ 2-metylo-4-( 2-metylobenzoiloamino) benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepiny do wytwarzania leku do leczenia ciężkiej niewydolności serca PL218069B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44887803P 2003-02-24 2003-02-24

Publications (2)

Publication Number Publication Date
PL373432A1 true PL373432A1 (pl) 2005-08-22
PL218069B1 PL218069B1 (pl) 2014-10-31

Family

ID=32908667

Family Applications (2)

Application Number Title Priority Date Filing Date
PL373432A PL218069B1 (pl) 2003-02-24 2004-02-23 Lek i kompozycja farmaceutyczna do zastosowania w leczeniu ciężkiej niewydolności serca oraz zastosowanie 5-hydroksy-7-chloro-1-[ 2-metylo-4-( 2-metylobenzoiloamino) benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepiny do wytwarzania leku do leczenia ciężkiej niewydolności serca
PL404315A PL404315A1 (pl) 2003-02-24 2004-02-23 Lek i kompozycja farmaceutyczna zawierajaca 5-hydroksy-7-chloro-1[2-metylo-4(2-metylobenzoiloamino)benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepine do leczenia ciezkiej niewydolnosci serca oraz zastosowanie tego zwiazku do wytwarzania leku

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL404315A PL404315A1 (pl) 2003-02-24 2004-02-23 Lek i kompozycja farmaceutyczna zawierajaca 5-hydroksy-7-chloro-1[2-metylo-4(2-metylobenzoiloamino)benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepine do leczenia ciezkiej niewydolnosci serca oraz zastosowanie tego zwiazku do wytwarzania leku

Country Status (23)

Country Link
US (2) US7423032B2 (pl)
EP (2) EP1596868B1 (pl)
JP (2) JP4771937B2 (pl)
KR (1) KR100706727B1 (pl)
CN (1) CN100577171C (pl)
AR (1) AR043259A1 (pl)
AT (1) ATE411803T1 (pl)
AU (2) AU2004212842B9 (pl)
BR (1) BRPI0405657A (pl)
CA (1) CA2493475A1 (pl)
CY (1) CY1108583T1 (pl)
DE (1) DE602004017283D1 (pl)
DK (1) DK1596868T3 (pl)
ES (1) ES2315640T3 (pl)
MX (1) MXPA05001623A (pl)
MY (1) MY143740A (pl)
NO (1) NO335369B1 (pl)
PL (2) PL218069B1 (pl)
PT (1) PT1596868E (pl)
RU (2) RU2346689C2 (pl)
SI (1) SI1596868T1 (pl)
TW (1) TWI322689B (pl)
WO (1) WO2004073716A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468390B2 (en) * 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
TWI322689B (en) * 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor
DE102005003632A1 (de) 2005-01-20 2006-08-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Katheter für die transvaskuläre Implantation von Herzklappenprothesen
US20070213813A1 (en) 2005-12-22 2007-09-13 Symetis Sa Stent-valves for valve replacement and associated methods and systems for surgery
PL1968990T3 (pl) 2005-12-27 2015-06-30 Otsuka Pharma Co Ltd Rozpuszczalny w wodzie związek benzoazepinowy i jego kompozycja farmaceutyczna
JP5076327B2 (ja) * 2006-02-01 2012-11-21 味の素株式会社 分岐鎖アミノ酸の心不全適応
US7896915B2 (en) 2007-04-13 2011-03-01 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
MX2009012164A (es) * 2007-05-15 2009-12-09 Otsuka Pharma Co Ltd Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia.
TWI405574B (zh) * 2007-06-21 2013-08-21 Otsuka Pharma Co Ltd 藥學固體製劑及其製造方法
WO2011104269A1 (en) 2008-02-26 2011-09-01 Jenavalve Technology Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US9044318B2 (en) 2008-02-26 2015-06-02 Jenavalve Technology Gmbh Stent for the positioning and anchoring of a valvular prosthesis
US10856978B2 (en) 2010-05-20 2020-12-08 Jenavalve Technology, Inc. Catheter system
CA2799459A1 (en) 2010-05-25 2011-12-01 Jenavalve Technology Inc. Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent
JP5477413B2 (ja) * 2012-04-24 2014-04-23 味の素株式会社 分岐鎖アミノ酸の心不全適応
CN105491978A (zh) 2013-08-30 2016-04-13 耶拿阀门科技股份有限公司 用于假体瓣膜的径向可折叠框架及其制造方法
EP3270825B1 (en) 2015-03-20 2020-04-22 JenaValve Technology, Inc. Heart valve prosthesis delivery system
EP3632378B1 (en) 2015-05-01 2024-05-29 JenaValve Technology, Inc. Device with reduced pacemaker rate in heart valve replacement
US11065138B2 (en) 2016-05-13 2021-07-20 Jenavalve Technology, Inc. Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath and loading system
CN110392557A (zh) 2017-01-27 2019-10-29 耶拿阀门科技股份有限公司 心脏瓣膜模拟
CN110174474B (zh) * 2019-05-24 2022-02-18 石家庄四药有限公司 复方电解质注射液(ⅱ)中l-苹果酸异构体的检测方法
CN112121051B (zh) * 2020-09-30 2021-06-18 郑州大学 莫扎伐坦在制备抗消化道肿瘤药物中的应用
US12171658B2 (en) 2022-11-09 2024-12-24 Jenavalve Technology, Inc. Catheter system for sequential deployment of an expandable implant

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01102124A (ja) 1987-10-14 1989-04-19 Kubota Ltd コンクリート構造体支持構造
US5753677A (en) * 1989-10-20 1998-05-19 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
WO1991005549A1 (en) 1989-10-20 1991-05-02 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
US5258510A (en) 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
AU657424B2 (en) 1992-07-02 1995-03-09 Otsuka Pharmaceutical Co., Ltd. Oxytocin antagonist
JPH0680641A (ja) 1992-09-01 1994-03-22 Otsuka Pharmaceut Co Ltd 光学活性な５−ヒドロキシベンゾアゼピン誘導体の製造法
TW354762B (en) 1993-02-23 1999-03-21 Otsuka Pharma Co Ltd Agent for prophylaxis or treatment of cataract
JP2694319B2 (ja) 1993-12-24 1997-12-24 大塚製薬株式会社 抗潰瘍剤
JP3002766B2 (ja) 1994-12-09 2000-01-24 大塚製薬株式会社 脳浮腫治療剤
JPH10120592A (ja) 1996-10-22 1998-05-12 Otsuka Pharmaceut Co Ltd メニエール病乃至メニエール症候群治療剤
JP4210355B2 (ja) * 1997-07-03 2009-01-14 大塚製薬株式会社 固形製剤組成物
WO2001054677A2 (en) 2000-01-26 2001-08-02 Warner-Lambert Company Ace inhibitor-vasopressin antagonist combinations
US20030103983A1 (en) * 2002-05-09 2003-06-05 Pressler Milton Lethan Ace inhibitor-vasopressin antagonist combinations
US20030008860A1 (en) * 2002-05-09 2003-01-09 Bakker-Arkema Rebecca Guggemos Treatment of congestive heart failure
EP1195166B1 (en) * 2000-10-04 2007-07-25 Astellas Pharma Inc. Use of a vasopressin antagonist such as conivaptan in the manufacture of a medicament for treating pulmonary hypertension
TWI322689B (en) * 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor

Also Published As

Publication number Publication date
NO335369B1 (no) 2014-12-01
EP1596868A4 (en) 2006-03-29
AU2004212842B9 (en) 2009-03-05
WO2004073716A1 (en) 2004-09-02
SI1596868T1 (sl) 2008-12-31
AR043259A1 (es) 2005-07-20
NO20050569D0 (no) 2005-02-02
RU2005102110A (ru) 2005-09-20
KR20050105972A (ko) 2005-11-08
DK1596868T3 (da) 2008-12-08
HK1084037A1 (zh) 2006-07-21
JP2006518731A (ja) 2006-08-17
ATE411803T1 (de) 2008-11-15
RU2008133654A (ru) 2010-02-20
TWI322689B (en) 2010-04-01
AU2004212842A1 (en) 2004-09-02
PL404315A1 (pl) 2013-08-05
JP4771937B2 (ja) 2011-09-14
KR100706727B1 (ko) 2007-04-12
MY143740A (en) 2011-07-15
DE602004017283D1 (de) 2008-12-04
CA2493475A1 (en) 2004-09-02
MXPA05001623A (es) 2005-04-25
CN1700919A (zh) 2005-11-23
US20080214523A1 (en) 2008-09-04
RU2346689C2 (ru) 2009-02-20
ES2315640T3 (es) 2009-04-01
AU2009201109A1 (en) 2009-04-09
BRPI0405657A (pt) 2005-07-19
PL218069B1 (pl) 2014-10-31
JP2011148806A (ja) 2011-08-04
US20050187210A1 (en) 2005-08-25
EP1596868A1 (en) 2005-11-23
NO20050569L (no) 2005-11-22
US7749993B2 (en) 2010-07-06
EP1596868B1 (en) 2008-10-22
EP2000142A1 (en) 2008-12-10
PT1596868E (pt) 2009-01-14
CY1108583T1 (el) 2014-04-09
US7423032B2 (en) 2008-09-09
TW200418489A (en) 2004-10-01
AU2004212842B2 (en) 2009-01-08
CN100577171C (zh) 2010-01-06

Similar Documents

Publication Publication Date Title
SI1596868T1 (sl) Metoda zdravljenja hude srčne odpovedi in zdravilo za njo
EP1680166A4 (en) METHOD AND DEVICE FOR THE TREATMENT OF HEART FAILURE
GB2398810B (en) Well treatment method and system
AU2003257613A1 (en) Catheter for treating irregular heart pulse
AU2003256253A8 (en) Aerosol for medical treatment and methods
EP1640035A4 (en) HEART TREATMENT APPARATUS AND HEART TREATMENT METHOD
AU2003303198A8 (en) Method for treating amyloid disease
AU2003213771A8 (en) Method for modification of radiotherapy treatment delivery
AU2002325435A8 (en) Medication and method for treating pathological syndrome
GB0201674D0 (en) Medical treatment
AU2002367023A8 (en) Compositions and methods for treating heart failure
AU2003232044A8 (en) Composition and method for dermatological treatment
EP1500401A4 (en) DRUGS FOR THE TREATMENT OF VASCULAR DISEASES
GB0218879D0 (en) Medical treatment
AU2003291536A8 (en) Method for the diagnosis and treatment of vascular disease
AU2002365057A8 (en) Compositions and methods for treating heart failure
ZA200502307B (en) Method for treating patients with massive blood loss
GB0208897D0 (en) New method of treatment
GB0307544D0 (en) Treatment method
GB2406865B (en) Well treatment system and method
GB0213198D0 (en) Method of treatment
GB0302691D0 (en) Treatment method
EP1841443A4 (en) METHOD AND SYSTEM FOR TREATING HEART ERRORS
GB0416872D0 (en) System and method for medical treatment
AUPS020602A0 (en) Treatment for heart failure

Legal Events

Date Code Title Description
RECP Rectifications of patent specification